Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.70 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | FLT4 | P35916 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | STK17B | O94768 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7845027 | 0.90 | EGFR (0.69) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL7846579 | 0.86 | ERBB2 (0.61) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL6383139 | 0.84 | EGFR (0.74) | EGFRERBB2PRKD3SRCPRKD1 | |
| SCHEMBL14092461 | 0.83 | EGFR (0.82) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL11019 | 0.83 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 | |
| Gefitinib SCHEMBL29351336 | 0.82 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL1734701 | 0.82 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 | |
| Gefitinib SCHEMBL29351046 | 0.82 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 | |
| Gefitinib SCHEMBL465143 | 0.82 | EGFR (1.00) | EGFRKDREPHB4ERBB2FLT4 | |
| SCHEMBL27315311 | 0.82 | EGFR (0.80) | EGFRKDREPHB4ERBB2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802608-A2 | COMPOUNDS&METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS&OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106643-A2 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | EGFR 310/4885KDR 2584/4885EPHB4 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.